Release date: 2009-07-07
In 2009, a groundbreaking hemostatic patch developed by Yangling Yuying Bio-Pharmaceutical Group Co., Ltd. made significant strides in the field of emergency medical care. This first-aid hemostatic patch, which carries original intellectual property rights, marked a major breakthrough in addressing the challenges of arterial injury and hemorrhage control in out-of-hospital settings. It provided critical support for life-saving interventions during emergencies when medical facilities were not immediately accessible.
According to reports, more than 80% of casualties during wartime died due to uncontrolled bleeding from traumatic injuries. Similarly, in peacetime, severe blood loss caused by natural disasters, accidents, or other incidents remains one of the leading causes of death and disability. As a result, there has been growing global interest in developing advanced hemostatic products, particularly those suitable for use in the field during emergencies. Currently, internationally recognized hemostatic solutions include Z-Medica’s hemostatic granules, Hemcon’s chitosan bandages, and dry fibrin dressings. While similar products exist in China, they often fall short in terms of effectiveness and reliability.
The "First Aid Hemostatic Patch" emerged as a game-changer in this field, filling a critical gap in trauma care. Clinical trials conducted at the National New Drug Research and Development Base of Xi’an Jiaotong University School of Medicine, as well as at Peking University People's Hospital and Xuanwu Hospital of Capital Medical University—both designated by the State Food and Drug Administration—demonstrated its ability to quickly and safely control bleeding from both arterial and venous injuries, as well as diffuse bleeding, within 3 to 5 minutes. This innovation significantly reduces mortality rates from traumatic incidents and brings hope to emergency first aid scenarios.
On December 26, 2008, the product received the Class III Medical Device Registration Certificate from the State Food and Drug Administration. It became the only external hemostatic product in China that successfully passed joint review by both drug and medical device regulatory authorities. Its introduction marked a milestone in China’s medical device industry and set a new standard for emergency care solutions worldwide.
Plant Extract,Natural Eleuthero Extract,Wolfberry Root Bark Extract,Portulaca Grandiflora Extract
Fufeng Sinuote Biotechnology Co.,Ltd. , https://www.sinuotebio.com